The Twelve Months

Safe & Green Holdings Reports Year-End 2023 Results

Retrieved on: 
星期三, 五月 8, 2024
Financial management, Sale, GAAP, MPA, Disability discrimination act, Housing, Disability, The Twelve Months, Depreciation, IRS, LOI, Strategic planning, Growth, Engineering, SGD, COVID-19, Loss, Homelessness, Adjustment, Bank statement, Veteran, Tunnel, Bookkeeping

MIAMI, May 08, 2024 (GLOBE NEWSWIRE) -- Safe & Green Holdings Corp. (NASDAQ: SGBX) ("Safe & Green Holdings" or the "Company"), a leading developer, designer, and fabricator of modular structures, reported results for the year ended December 31, 2023.

Key Points: 
  • MIAMI, May 08, 2024 (GLOBE NEWSWIRE) -- Safe & Green Holdings Corp. (NASDAQ: SGBX) ("Safe & Green Holdings" or the "Company"), a leading developer, designer, and fabricator of modular structures, reported results for the year ended December 31, 2023.
  • Tricia Kaelin, Chief Financial Officer at Safe & Green Holdings, stated, "During 2023, the Company successfully secured non-dilutive funding, which speaks to the strength of our assets as well as our ability to fund future growth without turning to the equity markets.
  • The infusion of capital is intended to free up working capital, providing further support for Safe & Green Holdings' growing customer demand and facilitating its aggressive expansion strategies.
  • The table below reconciles EBITDA and Adjusted EBITDA, both non-GAAP measures, to GAAP net gain (loss) attributable to common stockholders of Safe & Green Holdings Corp.

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Retrieved on: 
星期一, 四月 29, 2024
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Heng, NMPA, The Twelve Months, Vaccine, Enterovirus, District court, Court, GAAP, Person, EV71, WHO, Hearing, National Medical Products Administration, Hand, Exchange, Complaint, Sinovac Biotech, Privy council, Good, Annual report, Influenza, Infection, OrbiMed, Motion, Foot, Judgement, Rights, GMP, Clinical trial, Government, Appellate court, Medication, Capital, Ageing, Influenza vaccine, Cancer, Trust, Bank statement, HFMD, COVID-19, Growth, Hepatitis

The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.

Key Points: 
  • The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.
  • Sales for the second half of 2023 were $307.9 million, compared to $280.5 million in the prior year period.
  • R&D expenses in the second half of 2023 were $193.4 million, compared to $257.7 million in the prior year period.
  • The Company’s financial statements for the second half of 2023 are prepared and presented in accordance with U.S. GAAP.

American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
星期三, 三月 27, 2024
Proton, Growth, Three Months, Radiosurgery, Proton therapy, The Twelve Months, Partnership, Webcast, Patient, Sale, Cancer, Software, Overalls, Orlando Health, AMS, Marketing, Cobalt, Video game

Adjusted EBITDA, a non-GAAP financial measure, was $2,679,000 for the fourth quarter of 2023, compared to $2,161,000 for the fourth quarter of 2022.

Key Points: 
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,679,000 for the fourth quarter of 2023, compared to $2,161,000 for the fourth quarter of 2022.
  • Ray Stachowiak, Executive Chairman of American Shared Hospital Services, commented, “2023 was a good year for AMS with continual improvement each quarter.
  • Net income attributable to American Shared Hospital Services in the fourth quarter of 2023 was $415,000, or $0.06 per diluted share, compared to net income of $246,000, or $0.04 per diluted share, for the fourth quarter of 2022.
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,679,000 for the fourth quarter of 2023, compared to $2,161,000 for the fourth quarter of 2022.

LiveWorld Reports 2023 Annual Financial Results

Retrieved on: 
星期三, 三月 27, 2024
Digital Marketing, Social Media, Search Engine Optimization, Search Engine Marketing, Marketing, Content Marketing, Advertising, Communications, Social media, Australian Financial Review, Medicine, Investment, Growth, The Twelve Months

LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2023.

Key Points: 
  • LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2023.
  • Net income from operations of $214,000, or 2% of revenues
    Cash increased by $835,000 to $4.6 million from December 31, 2022
    “2023 was the fourth consecutive year of increased revenues while maintaining a positive net income,” remarked David Houston, Chief Financial Officer, LiveWorld.
  • “LiveWorld leads the market in unlocking the true value of social media marketing, with a combination of compliance, engagement, and insight solutions,” said Peter Friedman, Chairman & CEO, LiveWorld.
  • The lower income in 2023 was primarily due to a higher tax liability and investments for future growth of the company.

Solo Brands Announces Fourth Quarter and Fiscal Year 2023 Results Provides Full Year 2024 Guidance

Retrieved on: 
星期四, 三月 14, 2024
Fashion, Lifestyle, Retail, Consumer, Home Goods, Specialty, Conference, Growth, Three Months, The Twelve Months, Webcast, Common, Line of credit, Acquisition, Depreciation, DTC, Oru, GAAP, Term loan, Marketing, Video game

Solo Brands, Inc. (NYSE: DTC) (“Solo Brands” or “the Company”) today announced its financial results for the three and twelve month periods ended December 31, 2023.

Key Points: 
  • Solo Brands, Inc. (NYSE: DTC) (“Solo Brands” or “the Company”) today announced its financial results for the three and twelve month periods ended December 31, 2023.
  • Lower net sales resulted, in part, from a lack of significant new product launches in the fourth quarter of 2023 when compared to the fourth quarter of 2022.
  • Adjusted net income per Class A common stock(1)(2) was $0.13 per diluted share for the fourth quarter of 2023 compared to $0.25 for the fourth quarter of 2022.
  • A conference call to discuss the Company's fourth quarter and fiscal 2023 results is scheduled for March 14, 2024, at 8:30 a.m.

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

Retrieved on: 
星期三, 四月 3, 2024
Momentum, Patient, History, Sale, IP, Endometriosis, Depreciation, USD, Marketing, Regulation, Research, Classification, Webcast, Freezing, Woman, Breast cancer, ICE3, Food, Case Western Reserve University, Neoplasm, Cancer, LN2, GAAP, FDA, Annual general meeting, Health, Conference call, Growth, The Twelve Months, Recurrence, Society, Patent, Physician, Kidney cancer

CAESAREA, Israel, April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported sales as of and for the twelve months ended December 31, 2023 increased 26% compared to the twelve months ended December 31, 2022, as the Company continues to transition from a research and development and clinical phase company to a commercial phase company.

Key Points: 
  • Our U.S. commercial team is ready to launch marketing and distribution of ProSense® for breast cancer as we await the U.S. Food and Drug Administration's ("FDA") decision.
  • Should the FDA grant clearance, we believe this decision would further boost commercial demand in global markets where ProSense® already has approval for breast cancer."
  • "As we increased our commercial activities through medical conferences and added more distributors, we had a corresponding growth in 2023 revenues, system, and probe sales.
  • The FDA requested this data as part of IceCure's De Novo Classification Request for Marketing Authorization of ProSense® for the treatment of early-stage low-risk breast cancer.

INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR FISCAL YEAR 2023

Retrieved on: 
星期一, 四月 1, 2024
Medical device, Thyroid cancer, Growth, The Twelve Months, Third party, Calibration, Sale, IDAHO, Intellectual property, I-131, OTCQB, Nuclear medicine, Cryptocurrency

IDAHO FALLS, Idaho, April 1, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the twelve-month periods ended December 31, 2023.

Key Points: 
  • IDAHO FALLS, Idaho, April 1, 2024 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company" or "INIS") announces its financial results for the twelve-month periods ended December 31, 2023.
  • Revenue for the twelve months ended December 31, 2023, was $12.3 million compared to $11.2 million for the same period in 2022.
  • As of December 31, 2023, cash and cash equivalents improved to $2.7 million compared to $2.4 million as of December 31, 2022.
  • Shahe Bagerdjian, President & CEO of the Company, said, "The 2023 fiscal results are very encouraging; we posted the highest revenue in the company's history, and the company had positive cash flow from operating activities.

NewLake Capital Partners Reports Fourth Quarter and Full-Year 2023 Financial Results; Raises First Quarter 2024 Common Stock Dividend to $0.41 per Share

Retrieved on: 
星期一, 三月 11, 2024
Tenant, Comparison, FFO, The Twelve Months, Common stock, Table, Common, Conference, Fourth, Funds from operations, Environment, Holding company

NEW CANAAN, Conn., March 11, 2024 (GLOBE NEWSWIRE) -- NewLake Capital Partners, Inc. (OCTQX: NLCP) (the “Company” or “NewLake”), a leading provider of real estate capital to state-licensed cannabis operators, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and declared its first quarter of 2024 dividend.

Key Points: 
  • Anthony Coniglio, President and Chief Executive Officer, said, “We are pleased to deliver solid fourth quarter and full year financial results.
  • Declared a fourth quarter dividend of $0.40 per share of common stock, an increase of 2.6% year-over-year.
  • For the twelve months ended December 31, 2023, the Company declared dividends of $1.57 per share of common stock, an increase of 9.0% year-over-year.
  • The following tables present the Company’s investment activity for the twelve months ended December 31, 2023 (dollars in thousands):

Aemetis Reports 2023 Fourth Quarter and Year-End Results

Retrieved on: 
星期四, 三月 7, 2024
Engineering, Collection, Operating cost, The Twelve Months, Ethanol, Aviation, Renewable natural gas, Natural gas, Growth, Sale, CEQA, Authority, Adjustment, Carbon, D3, Construct, CO2, Public expenditure, Acceleration, IRA, Three Months, Investment, USDA, Video game

CUPERTINO, CA, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products, today announced its financial results for the fourth quarter and twelve months ended December 31, 2023.

Key Points: 
  • “Revenues were $70.8 million for the fourth quarter of 2023, an increase from $66.7 million for the fourth quarter of 2022.
  • Financial Results for the Three Months Ended December 31, 2023
    Revenues were $70.8 million for the fourth quarter of 2023, an increase from $66.7 million for the fourth quarter of 2022.
  • The ethanol gallons sold increased from 13.4 million gallons during the fourth quarter of 2022 to 15 million gallons during the fourth quarter of 2023.
  • Selling, general and administrative expenses rose from $7.5 million during the fourth quarter of 2022 to $9.8 million during the fourth quarter of 2023.

Universal Electronics Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
星期四, 二月 15, 2024
Software, Mobile, Wireless, Networks, Internet, Hardware, Consumer Electronics, Technology, Retail, Photography, Audio, Video, Telecommunications, Home Goods, The Twelve Months, UEI, Share repurchase, Growth, Use, District court, Adjustment, GAAP, Judgement, Universal Electronics, Patent, Intellectual property, IP, Three Months, Bank

Universal Electronics Inc. (UEI), (NASDAQ: UEIC) reported financial results for the three and twelve months ended December 31, 2023.

Key Points: 
  • Universal Electronics Inc. (UEI), (NASDAQ: UEIC) reported financial results for the three and twelve months ended December 31, 2023.
  • We are executing our efficiency initiatives, and our strong gross margins delivered better than expected earnings per share for the fourth quarter of 2023.
  • For a more detailed explanation of Non-GAAP measures, please see the Use of Non-GAAP Financial Metrics discussion, the Reconciliation of Adjusted Non-GAAP Financial Results and the Reconciliation of Adjusted Non-GAAP Financial Outlook and Financial Results, each located elsewhere in this press release.
  • ET / 1:30 p.m. PT, to discuss its fourth quarter and full year 2023 earnings results, review recent activity and answer questions.